To quantify the health-related quality of life (HRQoL) of bladder cancer (BC) patients around the time of diagnosis and to test the hypotheses of a 2-factors model for the QLQ-C30.
Within the Bladder Cancer Prognoses Programme (BCPP), a multicentre cohort study, sociodemographic data were collected using semi-structured face-to-face interviews. Answers to the QLQ-C30 were transformed into a scale from 0 to 100. HRQoL data was analysed in multivariate analyses. The hypothesized two-factor (Physical and Mental Health) domain structure of the QLQ-C30 was also tested with confirmatory factor analyses (CFA).
Totally, 1,160 (78%) participants completed the questionnaire after initial visual diagnosis and before pathological confirmation. Despite NMIBC having a higher HRQoL than MIBC, only the domain Role Functioning was clinically significantly better in NMIBC patients. Age, gender, BC stage and comorbidity all had a significant influence on QLQ-C30 scores. CFA showed an overall good fit of the hypothesized 2-factors model.
This study has identified a baseline reference value for HRQoL for BC patients, which allows for better evaluation of any changes in HRQoL as disease progresses or after treatment. In addition, a 2-factors (Physical and Mental Health) model was developed for the QLQ-C30. This article is protected by copyright. All rights reserved.
BJU international. 2019 May 11 [Epub ahead of print]
Evan Yi-Wen Yu, Duncan Nekeman, Neil K Aaronson, Lucinda J Billingham, Nicholas D James, K K Cheng, Richard T Bryan, Anke Wesselius, Maurice P Zeegers
NUTRIM School for Nutrition and Translational Research in Metabolism, University of Maastricht, Maastricht, the Netherlands., Department of Public Health, Epidemiology and Biostatistics, School of Health and Population Sciences, University of Birmingham, Birmingham, United Kingdom., Netherlands Cancer Institute-Antonie van Leeuwenhoek Hospital, Department of Psychosocial Research en Epidemiology, Amsterdam, the Netherlands., MRC Midland Hub for Trials Methodology Research and Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom., University of Birmingham, School of Cancer Sciences, Birmingham, United Kingdom., CAPHRI School for Public Health and Primary Care, University of Maastricht, Maastricht, the Netherlands.